Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection

Journal of Antimicrobial Chemotherapy

Volumn 74, Issue 3, 2019, Pages 654-662

  Fukao, Keita ^a   Noshi, Takeshi ^a   Yamamoto, Atsuko ^a   Kitano, Mitsutaka ^a   Ando, Yoshinori ^a   Noda, Takahiro ^a   Baba, Kaoru ^a   Matsumoto, Kazumi ^a   Higuchi, Naoko ^a   Ikeda, Minoru ^a   Shishido, Takao ^a   Naito, Akira ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BALOXAVIR MARBOXIL; GAMMA INTERFERON; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; OSELTAMIVIR; ANTIVIRUS AGENT; BALOXAVIR; OXAZINE DERIVATIVE; PYRIDINE DERIVATIVE; THIEPIN DERIVATIVE; TRIAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BODY WEIGHT; BODY WEIGHT LOSS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; CYTOPATHOGENIC EFFECT; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; EC50; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A (H1N1); INFLUENZA A VIRUS (A/PUERTO RICO/8/1934(H1N1)); LUNG WEIGHT; MONOTHERAPY; MOUSE; NONHUMAN; SURVIVAL TIME; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECT; INFLUENZA A VIRUS; ORAL DRUG ADMINISTRATION; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; INFLUENZA A VIRUS; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; OSELTAMIVIR; OXAZINES; PYRIDINES; SURVIVAL ANALYSIS; THIEPINS; TREATMENT OUTCOME; TRIAZINES; UNITED STATES;

EID: 85061036083     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky462     Document Type: Article

References (39)

1. Su B, Wurtzer S, Rameix-Welti MA et al. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One 2009; 4: e8495.
2. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med 2005; 353: 1363-73.
3. Sheu TG, Deyde VM, Okomo-Adhiambo M et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 2008; 52: 3284-92.
4. Muthuri SG, Venkatesan S, Myles PR et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395-404.
5. Heneghan CJ, Onakpoya I, Thompson M et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348: g2547.
6. Jefferson T, Jones M, Doshi P et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348: g2545.
7. Jones M, Jefferson T, Doshi P et al. Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Clin Microbiol Infect 2015; 21: 217-21.
8. Kash JC, Taubenberger JK. The role of viral, host, and secondary bacterial factors in influenza pathogenesis. Am J Pathol 2015; 185: 1528-36.
9. Taubenberger JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol 2008; 3: 499-522.
10. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59: 1057-62.
11. DuBois RM, Slavish PJ, Baughman BM et al. Structural and biochemical basis for development of influenza virus inhibitors targeting the PA endonuclease. PLoS Pathog 2012; 8: e1002830.
12. Plotch SJ, Bouloy M, Ulmanen I et al. A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell 1981; 23: 847-58.
13. Yuan P, Bartlam M, Lou Z et al. Crystal structure of an avian influenza polymerase PA(N) reveals an endonuclease active site. Nature 2009; 458: 909-13.
14. Omoto S, Speranzini V, Hashimoto T et al. Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep 2018; 8: 9633.
15. Noshi T, Yamamoto A, Kawai M et al. S-033447/S-033188, a novel small molecule inhibitor of cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against clinical strains. In: Abstracts of IDWeek, New Orleans, LA, USA, 2016.Poster 645.
16. Noshi T, Tachibana H, Yamamoto A et al. S-0033447/S-033188, a novel small molecule inhibitor of Cap-dependent endonuclease of influenza A and B virus: in vitro antiviral activity against laboratory strains of influenza A and B virus in Madin-Darby Canine Kidney Cells. In: Abstracts of OPTIONS IX, Chicago, IL, USA, 2016. Poster 418.
17. Shishido T, Omoto S, Ishida K et al. S-033447/S-033188, a novel small molecule inhibitor of Cap-dependent endonuclease (CEN) of influenza A and B virus: in vitro inhibitory effect of S-033447 on CEN activities of influenza A and B virus. In: Abstracts of OPTIONS IX, Chicago, IL, USA, 2016. Poster 185.
18. Hayden FG, Sugaya N, Hirotsu N et al. Baloxavir marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med 2018; 379: 913-23.
19. Ison MG. Finding the right combination antiviral therapy for influenza. Lancet Infect Dis 2017; 17: 1221-2.
20. Koszalka P, Tilmanis D, Hurt AC. Influenza antivirals currently in latephase clinical trial. Influenza Other Respir Viruses 2017; 11: 240-6.
21. Newton AH, Cardani A, Braciale TJ. The host immune response in respiratory virus infection: balancing virus clearance and immunopathology. Semin Immunopathol 2016; 38: 471-82.
22. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
23. Flannery AH, Thompson Bastin ML. Oseltamivir dosing in critically ill patients with severe influenza. Ann Pharmacother 2014; 48: 1011-8.
24. Sidwell RW, Barnard DL, Day CW et al. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845-51.
25. Garigliany MM, Habyarimana A, Lambrecht B et al. Influenza A strain-dependent pathogenesis in fatal H1N1 and H5N1 subtype infections of mice. Emerg Infect Dis 2010; 16: 595-603.
26. Julkunen I, Melén K, Nyqvist M et al. Inflammatory responses in influenza A virus infection. Vaccine 2000; 19 Suppl 1: S32-7.
27. Smee DF, Hurst BL, Wong MH et al. Combinations of oseltamivir and peramivir for the treatment of influenza A (H1N1) virus infections in cell culture and in mice. Antiviral Res 2010; 88: 38-44.
28. Smee DF, Tarbet EB, Furuta Y et al. Synergistic combinations of favipiravir and oseltamivir against wild-type pandemic and oseltamivir-resistant influenza A virus infections in mice. Future Virol 2013; 8: 1085-94.
29. Marathe BM, Wong SS, Vogel P et al. Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep 2016; 6: 26742.
30. Paules CI, Lakdawala S, McAuliffe JM et al. The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J Infect Dis 2017; 216: 356-65.
31. Duval X, van der Werf S, Blanchon T et al. Efficacy of oseltamivirzanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7: e1000362.
32. Zhang Y, Gao H, Liang W et al. Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for influenza A (H7N9) infection: a retrospective study. BMC Infect Dis 2016; 16: 76.
33. Noshi T, Sato K, Ishibashi T et al. Pharmacokinetic and pharmacodynamic analysis of S-033188/S-033447, a novel inhibitor of influenza virus Cap-dependent endonuclease, in mice infected with influenza A virus. In: Abstracts of the 27th ECCMID, Vienna, Austria, 2017. Poster 1973.
34. Koshimichi H, Ishibashi T, Kawaguchi N et al. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir marboxil in healthy adults: phase 1 study findings. Clin Drug Investig 2018; doi: 10.1007/s40261-018-0710-9.
35. Sharma G, Champalal Sharma D, Hwei Fen L et al. Reduction of influenza virus-induced lung inflammation and mortality in animals treated with a phosophodisestrase-4 inhibitor and a selective serotonin reuptake inhibitor. Emerg Microbes Infect 2013; 2: e54.
36. Ward P, Small I, Smith J et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55 Suppl 1: i5-21.
37. Fukao K, Ando Y, Noshi T et al. One day oral dosing of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, exhibited significant reduction of viral titer and prolonged survival in mice infected with influenza B virus. In: Abstracts of the 27th ECCMID, Vienna, Austria, 2017. Poster 2175.
38. Taniguchi K, Ando Y, Noshi T et al. Inhibitory effect of S-033188, a novel inhibitor of influenza virus Cap-dependent endonuclease, against avian influenza A/H7N9 virus in vitro and in vivo. In: Abstracts of ESWI, Riga, Latvia, 2017. Abstract SPA4P09.
39. Taniguchi K, Ando Y, Noshi T et al. Inhibitory effect of S-033188/S-033447, a novel inhibitor of influenza virus cap-dependent endonuclease, against a highly pathogenic avian influenza virus A/H5N1. In: Abstracts of the 27th ECCMID, Vienna, Austria, 2017. Poster 1974.